You are here

Novel soluble nanopolymers for enrichment of low abundant phosphoproteins

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA162767-01A1
Agency Tracking Number: R43CA162767
Amount: $300,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA09-189
Timeline
Solicitation Year: 2012
Award Year: 2012
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1281 WIN HENTSCHEL BLVD
WEST LAFAYETTE, IN -
United States
DUNS: 965433258
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ANTON ILIUK
 (765) 430-1592
 anton.iliuk@tymora-analytical.com
Business Contact
 VICKY TSENG
Phone: (765) 430-1592
Email: vickyt@tymora-analytical.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): With recent technical advances, multiple important signaling pathways that may be the causes of human malignancy have continuously been discovered and dissected. The vast majority of these signaling pathways involve reversible protein phosphorylation, and the information on the location and dynamics of phosphorylation provides important mechanisms on how the signaling networks function and interact. While translational research gradually shifts from lab models to clinical samples, with the ultimate goal of identifying cancer biomarkers, a simple and reliable phosphorylation assay method is still missing for routine detection of phosphorylation in complex and typically heterogeneous clinical samples. Through this NIH SBIR Phase I study we will develop soluble nanopolymer-based reagents, termed PolyMAC (Polymer-based Metal Ion Affinity Capture), into commercial products for the highly efficient isolation of phosphopeptides. This novel design takes advantage of not only theproperties of multifunctionalized nanoparticles, but more importantly, the soluble nature of the molecule, allowing for the chelation of a limited amount of phosphopeptides in the solution phase for optimum efficiency and maximum yield. We propose to finalize optimization and scalability of the reagents as commercial products. In addition, high throughput formats for comprehensive phosphoproteomic analyses will be developed to address needs of many cancer biology and proteomics research labs/facilities.PUBLIC HEALTH RELEVANCE: Protein phosphorylation relates to the onset and development of many cancer types and a highly efficient technology for phosphorylation analysis is critical for cancer research. This NIH SBIR will support an effort to develop an innovative technology into commercial products that equip researchers with powerful tools and new directions to combat the devastating disease.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government